Why does Vanguard, one of the most well known for good solid investing, think NNVC is worth now holding as they do?
Well it just could be that;
NNVC therapeutic efficacy testing show remarkable results. Standardized test protocols with mice specially developed by those in the medical research community to have human susceptibility traits injected with 1000x viral loads required to ensure death. Standard industry protocols that measure efficacy by the time it takes to die for a treated mouse versus the control mice. Unprecedentedly, large percentages actually survive! Almost unheard of efficacy!
NNVC therapeutics shown to have similar efficacy in both injectable and oral forms.
NNVC therapeutics used in both forms show no apparent toxicity issues to date. Specific testing being currently planned and prepared for to verify.
From a comparative and historical perspective, stock dilution has been minimal demonstrating good stewardship and results per unit dollar achievement.
NNVC’s work good enough that is was awarded an orphan drug development designation in both the United States and Europe.
NNVC work good enough to now be an official candidate for a FDA Priority Review Voucher.
NNVC science independently confirmed by independent researchers in the area of pathogenesis and epidemiology of infectious diseases.
NNVC currently has sufficient funds to support 2 years of operations and into first human trials.
NNVC major insider purchases more shares from the open market in recent weeks.
NNVC therapeutics appear to be of a programmable design that can target nearly any type of virus in a matter of weeks!
Oh, and that is just to name a few possible reasons.
In the not too distant future, it just might be an NNVC nanoviricide that saves your life, or the life of a loved one. Do your own DD. Beware of misinformation. Read, study, think; a process that behooves us all.
Wishing all the best of good buys!
HS
